GSK
NYSE · Healthcare
GSK plc
$52.87
+0.70 (+1.34%)
GSK News30 articles
FTSE 100 Gains as Oil Earnings and BoE Decision Loom
The FTSE 100 closed at 10,736.23, up 1.28% for the week. Energy is expected to contribute 62% of incremental earnings growth for the STOXX 600, with the BoE widely anticipated to hold rates steady.
GSK faces £3.6B revenue gap ahead of Tuesday strategy update
GSK faces a £3.63 billion revenue gap versus its 2031 target of £40 billion ahead of its strategy update on July 28. The shortfall persists despite oncology growth.
GSK Plummets After Failed Cough Drug Trial Wipes Out £2.36B
GSK shares fell 3% after a phase III trial failure for its chronic cough drug camlipixant erased £2.36 billion in market value, more than the cost of acquiring BELLUS.
FTSE 100 Slips Despite Strong UK GDP; Takeover Bids for Rotork, Gooch & Housego
FTSE 100 drops 52 points to 10,464 despite UK GDP rising 0.8% in three months. Rotork, Gooch & Housego, and Ramsdens agree to takeover bids.
Moderna Plunges 11% as EU Vaccine Deal Lacks Minimum Purchase Guarantee
Moderna stock dropped 11.3% after the EU's RSV vaccine deal lacked a minimum purchase commitment, adding to investor worries about sales and cash burn.
FTSE 100 Dips as AstraZeneca Drug Trial Disappoints
London's FTSE 100 fell as AstraZeneca dropped nearly 9% on a trial miss. The FTSE 250 rose, splitting the market. Oil and Middle East risks persist.
Moderna Surges 10% as Flu Vaccine Hopes Add $2.9B to Market Cap
Moderna shares surged over 10% in after-hours trading, adding roughly $2.9 billion in market value as investor enthusiasm for its flu vaccine pipeline continues to build.
AbbVie Acquires Apogee Therapeutics for $10.9B in Cash, Bolstering Pipeline
AbbVie announced a $10.9 billion cash acquisition of Apogee Therapeutics, adding a promising eczema treatment to its pipeline as it seeks to offset declining Humira sales.
GSK's $10.6B Nuvalent Buyout Drives Shares Near $124 Offer Price
Nuvalent stock rose 39.28% to $123.25 after GSK agreed to acquire the biotech for $124/share in cash, narrowing the spread to 0.6% as investors pivot to merger-arb dynamics and FDA dates.
Tech Stocks Slide, Oil Surges After US Strikes on Iran; CPI in Focus
US stock futures declined and oil prices advanced following US military strikes on Iran, intensifying a selloff in technology shares. Markets are now focused on Wednesday's inflation data and the anticipated SpaceX IPO.
Wall Street Mixed as AI Rally Faces Key Inflation Test
U.S. stocks traded mixed Tuesday as the Dow and S&P 500 posted modest gains while the Nasdaq dipped, with market focus on upcoming inflation data and AI sector strength.
GSK's $10.6B Nuvalent Bid Drives Stock Near Offer Price
Nuvalent shares jumped 38.9% to $122.93 after GSK's $10.6 billion buyout offer, as investors bet on the deal closing with two lead lung-cancer drugs under FDA review.
GSK Acquires Nuvalent for $10.6B in Oncology Push Ahead of HIV Patent Cliff
GSK buys Nuvalent for $10.6B, paying a 40% premium, to strengthen its oncology portfolio and offset upcoming HIV drug patent losses.
Lilly Expands Vaccine Portfolio with $3.83B Triple Acquisition
Eli Lilly acquires Curevo, LimmaTech, and Vaccine Company for up to $3.83B, gaining vaccine candidates for shingles, staph, and Epstein-Barr virus. Shares rose 5%.
Pfizer's COVID Patent Woes Persist as Investors Eye Growth Beyond Vaccines
A Delaware federal judge dismissed Acuitas Therapeutics' attempt to clear Pfizer's Comirnaty vaccine from GSK patent claims, leaving the patent dispute unresolved. Pfizer shares fell 1.42% to $25.68.
Moderna Jumps 10% on Hantavirus Vaccine Push as Cruise Ship Outbreak Revives mRNA Hopes
Moderna shares rose 10% on Friday after the company revealed early-stage work on a hantavirus vaccine, spurred by a deadly Andes virus outbreak on the MV Hondius cruise ship.
Mirum Surges on Volixibat Success in PSC Itch Trial, FDA Filing Targeted
Mirum Pharmaceuticals announced volixibat met its primary endpoint in a Phase 2b trial for PSC, reducing itch scores. Shares rose 9%. The company plans a pre-NDA FDA meeting this summer and a U.S. filing in H2 2026.
FTSE 100 Slides as Healthcare Stocks Weigh Despite Earnings Beats
The FTSE 100 slipped 0.6% as healthcare giants AstraZeneca and GSK declined despite topping profit forecasts, while Lloyds Banking Group's profit jump failed to lift sentiment.
Algoma Central, GSK, AT&T Lead Market Moves as Bitcoin Pool Mines Second Block
Algoma Central surpassed its 50-day moving average after a dividend hike, while GSK shares surged to a multi-decade peak. AT&T's valuation suggests significant upside, and a novel bitcoin mining pool confirmed its hybrid model.
Pfizer Shares Dip as GSK RSV Vaccine Gains Ground, Eliquis Data Provides Support
Pfizer shares declined 1% to $26.60 Friday after GSK secured expanded FDA approval for its RSV vaccine, challenging Pfizer's market position. Encouraging clinical results for blood thinner Eliquis helped cushion the drop.
GSK Expands Share Repurchases, Outlines 2026 Growth Strategy Under New CEO
GSK has acquired 650,000 shares for treasury and published its 2025 annual report, showing £32.7B in turnover. CEO Luke Miels forecasts continued profitable growth for 2026.
GSK Advances Pipeline with $2.2B RAPT Buy, Continues Share Repurchases
GSK shares gained after finalizing its $2.2 billion purchase of RAPT Therapeutics, acquiring a Phase IIb food allergy candidate, and disclosed further share repurchases as part of an ongoing program.
GSK Shares Dip Amid Oil Price Surge, Buyback Activity and FDA Decision in Focus
GSK's stock declined alongside the FTSE 100 as geopolitical tensions drove oil prices higher, reigniting inflation concerns. The pharmaceutical firm also reported recent buyback activity and faces a crucial FDA verdict later this month.
GSK Shares Dip Amid Oil Price Surge, Buyback Activity and FDA Decision in Focus
GSK's stock declined alongside the FTSE 100 as geopolitical tensions drove oil prices higher, reigniting inflation concerns. The company also reported fresh share repurchase activity.
GSK Shares Edge Higher Amid Buyback Activity and Consultancy Fallout
GSK plc shares gained 0.4% in early London trading while the company executed share buybacks and cut ties with consultancy Global Counsel amid reputational concerns.
GSK Stock Dips on Ex-Dividend Date and Arexvy Vaccine Data Release
GSK shares declined 0.4% in early London trading, influenced by the stock going ex-dividend and the release of new real-world effectiveness data for its respiratory syncytial virus vaccine Arexvy.
GSK Gains on EU Asthma Drug Approval and £450M Share Repurchase
GSK shares advanced after the European Commission approved its asthma drug Exdensur and the company launched a £450 million share repurchase. New data also highlighted the effectiveness of its RSV vaccine.
GSK Launches £450M Share Buyback Tranche, Part of £2B Program
GSK has initiated a new £450 million share repurchase tranche, a component of its broader £2 billion capital return program. The company's shares edged higher ahead of the launch.
Haleon Shares Dip as Wellington Discloses 4.97% Stake Ahead of Key Earnings
Haleon's stock declined slightly in London trading after a regulatory filing revealed Wellington Management holds a significant stake. Investors are focused on the company's full-year results due February 25 for updated guidance and capital return plans.
GSK Shares Dip on China Vaccine Timeline and Executive Stock Sales
GSK shares fell 1.5% in early London trading as China's regulatory review for its Arexvy RSV vaccine is set for a 2027 decision. The decline coincided with disclosures of executive share sales to cover tax obligations.